This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.

The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.

Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.

By accessing this website you accept this legal notice and expressly confirm your status as a healthcare professional.

More

Throughout the year, Novo Nordisk research is presented at several major congresses. We welcome you to explore the Novo Nordisk sponsored science that is presented using ScienceHub, which gives you free access to a comprehensive collection of digital features extending the official congress materials. The materials include audio poster tours, infographics, podcasts, videos featuring our presenters and supplementary slide decks.

Rounding off 2021, Novo Nordisk research was featured at the congress of the International Diabetes Federation (IDF) , which took place as a virtual event in the beginning of December. The IDF congress is held every two years, offering a forum to exchange and develop insights into a wide spectrum of diabetes-related topics. There is a core focus on the latest scientific advances in diabetes care and beyond, and other recurrent themes include efforts to improve diabetes education and awareness.

This year, the Novo Nordisk-related presentations focused mostly on the real-world use of the combination of insulin degludec and insulin aspart.